Interleukin 35 Protein (IL35) (AA 21-229, AA 57-253) (Fc Tag)

Produktnummer ABIN6253337

Produktdetails

Target: Interleukin 35 (IL35)

Protein-Typ: Recombinant

Proteineigenschaft: AA 21-229, AA 57-253

Spezies: Human

Quelle: CHO Cells

Aufreinigungstag / Konjugat: Dieses Interleukin 35 Protein ist gelabelt mit Fc Tag.

Verwendungszweck: IL-35 (human):Fc (human) (rec.)

Spezifität: The human IL-35 complex composed of the Ebi3 subunit (aa 21-229) and the IL-12a (p35) subunit (aa 57-253) is fused through a polypeptide linker to the Fc portion of human IgG1.

Produktmerkmale: Protein. The human IL-35 complex composed of the Ebi3 subunit (aa 21-229) and the IL-12a (p35) subunit (aa 57-253) is fused through a polypeptide linker to the Fc portion of human IgG1. Source: CHO cells. Endotoxin content: <0.06EU/μg protein (LAL test, Lonza). Lyophilized from 0.2μm-filtered solution in PBS. Purity: >98 % (SDS-PAGE). Interleukin-35 (IL-35) is a novel IL-12 family cytokine produced by regulatory T cells (Treg) but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of EBI3 (Epstein-Barr-Virus-induced gene 3) and IL-12a (p35). EBI3 is a downstream target of Foxp3, a transcription factor required for Treg-cell development and function, and thus Treg-cell restriction of IL35 occurs. Regulatory T cells are essential for maintaining self tolerance and preventing autoimmunity, and IL-35 is identified as a molecule that mediates the immune suppression function of Treg-cell. As an inhibitory cytokine, IL-35 induces proliferation of Treg-cell populations but suppresses Th17 cell development. Studies in mice show the absence of either IL-35 chain from Treg-cell reduces the cells' ability to suppress inflammation using an experimental model for inflammatory bowel disease. IL-35 is suggested as a potential target of immunotherapy.

Reinheit: >98 % (SDS-PAGE)

Endotoxin-Niveau: <0.06EU/μg protein (LAL test, Lonza).

Biological Activity Comment: Bioactivity was measured in a cell proliferation assay using anti-CD3 activated human peripheral mononuclear cells.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Konzentration: Lot specific

Buffer: Lyophilized from 0.2μm-filtered solution in PBS.

Handhabung: Avoid freeze/thaw cycles.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung:

Short Term Storage: +4°C

Long Term Storage: -20°C

Use & Stability: Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.

Antigendetails

Target: Interleukin 35 (IL35)

Andere Bezeichnung: IL-35 (IL35 Produkte)

Hintergrund:

Alternate Names/Synonyms: Interleukin-35

Product Description: Interleukin-35 (IL-35) is a novel IL-12 family cytokine produced by regulatory T cells (Treg) but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of EBI3 (Epstein-Barr-Virus-induced gene 3) and IL-12a (p35). EBI3 is a downstream target of Foxp3, a transcription factor required for Treg-cell development and function, and thus Treg-cell restriction of IL35 occurs. Regulatory T cells are essential for maintaining self tolerance and preventing autoimmunity, and IL-35 is identified as a molecule that mediates the immune suppression function of Treg-cell. As an inhibitory cytokine, IL-35 induces proliferation of Treg-cell populations but suppresses Th17 cell development. Studies in mice show the absence of either IL-35 chain from Treg-cell reduces the cells' ability to suppress inflammation using an experimental model for inflammatory bowel disease. IL-35 is suggested as a potential target of immunotherapy.

NCBI Accession: NP_000873